Last Price$437.20.0%
Market Cap$36.1B
LTM EBIT to Interest coverage
61.4x
5Y avg
27.3x
Medical - Diagnostics & Research industry
median
(14.3x)
Stock quality & Intrinsic value
7/10
(0.5%) overvalued
IDEXX Laboratories, Inc. EBIT to Interest coverage
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBIT to Interest coverage | 0.0x | 0.0x | 0.0x | 0.0x | 37.6x | 123.1x | 116.4x | 131.0x | 134.9x | 76.2x | 19.0x | 11.2x | 12.3x | 12.9x | 14.6x | 18.1x | 21.3x | 31.7x | 23.2x | 26.4x |
Overvalued or undervalued?
Check the intrinsic value for IDXX
and see if it's the right time to invest.
IDEXX Laboratories, Inc. (IDXX) EBIT to Interest coverage comparison analysis
General
LTM EBIT to Interest coverage
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
IDEXX Laboratories, Inc.IDXX
61.4x
8.7%
25.2%
23.1%
Median Peer Set
15.2x
(1.7%)
(7.2%)
11.6%
Agilent Technologies, Inc.A
32.2x
(4.7%)
5.0%
19.8%
Danaher CorporationDHR
31.2x
(0.1%)
(17.9%)
16.3%
Illumina, Inc.ILMN
18.1x
(2.9%)
4.6%
(28.0%)
Mettler-Toledo International Inc.MTD
16.1x
2.2%
12.7%
22.3%
Quest Diagnostics IncorporatedDGX
15.5x
(6.4%)
(6.5%)
9.2%
Waters CorporationWAT
14.9x
(0.5%)
(7.9%)
21.7%
Laboratory Corporation of America HoldingsLH
13.6x
(18.3%)
(65.8%)
3.4%
Thermo Fisher Scientific Inc.TMO
9.7x
(4.6%)
(12.4%)
14.0%
IQVIA Holdings Inc.IQV
3.4x
2.8%
2.4%
8.9%
Natera, Inc.NTRA
(19.3x)
32.0%
(32.1%)
(40.2%)
IDXX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 549.2 0.0% | 638.1 16.2% | 739.1 15.8% | 922.6 24.8% | 1,024.0 11.0% | 1,031.6 0.7% | 1,103.4 7.0% | 1,218.7 10.4% | 1,293.3 6.1% | 1,377.1 6.5% | 1,485.8 7.9% | 1,601.9 7.8% | 1,775.4 10.8% | 1,969.1 10.9% | 2,213.2 12.4% | 2,406.9 8.8% | 2,706.7 12.5% | 3,215.4 18.8% | 3,367.3 4.7% | 3,661.0 8.7% |
| Cost of Goods Sold (COGS) | 270.2 | 315.2 | 359.6 | 459.0 | 494.3 | 505.4 | 524.8 | 572.2 | 594.2 | 620.9 | 669.7 | 711.6 | 800.0 | 871.7 | 971.7 | 1,041.4 | 1,135.6 | 1,325.9 | 1,363.0 | 1,471.0 |
% margin | 279.0 50.8% | 322.9 50.6% | 379.5 51.3% | 463.5 50.2% | 529.8 51.7% | 526.3 51.0% | 578.6 52.4% | 646.5 53.0% | 699.1 54.1% | 756.1 54.9% | 816.1 54.9% | 890.3 55.6% | 975.4 54.9% | 1,097.4 55.7% | 1,241.5 56.1% | 1,365.5 56.7% | 1,571.0 58.0% | 1,889.4 58.8% | 2,004.3 59.5% | 2,190.0 59.8% |
| Operating Expenses | 171.0 | 207.6 | 251.6 | 327.3 | 357.3 | 350.3 | 374.7 | 410.3 | 436.6 | 489.4 | 555.9 | 582.1 | 625.2 | 684.4 | 750.2 | 812.7 | 876.5 | 957.4 | 1,105.6 | 1,092.8 |
| Research & Development Expenses (R&D) | 35.4 | 40.9 | 53.6 | 67.3 | 70.6 | 65.1 | 68.6 | 76.0 | 82.0 | 88.0 | 98.3 | 99.7 | 101.1 | 109.2 | 117.9 | 133.2 | 141.2 | 161.0 | 254.8 | 191.0 |
| Selling, General & Administrative Expenses (SG&A) | 135.6 | 166.6 | 198.0 | 260.0 | 285.3 | 285.2 | 306.1 | 334.2 | 354.6 | 401.4 | 457.6 | 482.5 | 524.1 | 575.2 | 632.3 | 679.5 | 735.3 | 796.4 | 850.8 | 901.9 |
% margin | 108.0 19.7% | 115.3 18.1% | 127.9 17.3% | 136.2 14.8% | 172.5 16.8% | 176.0 17.1% | 203.9 18.5% | 236.2 19.4% | 262.6 20.3% | 266.8 19.4% | 260.3 17.5% | 299.9 18.7% | 350.2 19.7% | 413.0 21.0% | 491.3 22.2% | 552.8 23.0% | 694.5 25.7% | 932.0 29.0% | 898.8 26.7% | 1,097.1 30.0% |
| Interest Income | 3.1 | 3.1 | 0.0 | 0.0 | 2.3 | 0.5 | 0.7 | 1.7 | 1.9 | 1.9 | 1.7 | 2.5 | 3.7 | 5.3 | 1.2 | 0.4 | 0.6 | 0.4 | 1.1 | 5.6 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 4.6 | 1.4 | 1.8 | 1.8 | 1.9 | 3.5 | 13.7 | 26.8 | 28.4 | 32.0 | 33.6 | 30.6 | 32.5 | 29.4 | 38.8 | 41.6 |
| Pre-tax Income | 111.1 | 118.5 | 130.8 | 134.8 | 170.2 | 174.5 | 202.1 | 234.4 | 260.6 | 263.3 | 246.6 | 273.1 | 321.8 | 381.1 | 457.7 | 522.2 | 662.0 | 902.7 | 860.0 | 1,061.2 |
% effective tax rate | 33.2 29.9% | 40.7 34.3% | 37.2 28.5% | 40.8 30.3% | 54.0 31.7% | 52.3 30.0% | 60.8 30.1% | 72.7 31.0% | 82.3 31.6% | 75.5 28.7% | 64.6 26.2% | 81.0 29.7% | 99.8 31.0% | 117.8 30.9% | 80.7 17.6% | 94.4 18.1% | 79.9 12.1% | 157.8 17.5% | 180.9 21.0% | 216.1 20.4% |
% margin | 78.3 14.3% | 78.3 12.3% | 93.7 12.7% | 94.0 10.2% | 116.2 11.3% | 122.2 11.8% | 141.3 12.8% | 161.8 13.3% | 178.3 13.8% | 187.8 13.6% | 181.9 12.2% | 192.1 12.0% | 222.0 12.5% | 263.1 13.4% | 377.0 17.0% | 427.7 17.8% | 581.8 21.5% | 744.8 23.2% | 679.1 20.2% | 845.0 23.1% |
| EPS | 0.57 | 0.60 | 0.75 | 0.77 | 0.97 | 1.04 | 1.23 | 1.43 | 1.62 | 1.77 | 1.82 | 2.07 | 2.47 | 3.00 | 4.34 | 4.97 | 6.82 | 8.74 | 8.12 | 10.17 |
| Diluted EPS | 0.55 | 0.57 | 0.71 | 0.73 | 0.94 | 1.00 | 1.19 | 1.39 | 1.59 | 1.74 | 1.79 | 2.05 | 2.44 | 2.94 | 4.26 | 4.89 | 6.71 | 8.60 | 8.03 | 10.06 |
% margin | 126.5 23.0% | 139.7 21.9% | 157.7 21.3% | 177.3 19.2% | 223.6 21.8% | 226.2 21.9% | 250.5 22.7% | 284.7 23.4% | 316.2 24.4% | 322.3 23.4% | 319.8 21.5% | 370.3 23.1% | 431.7 24.3% | 501.4 25.5% | 575.7 26.0% | 643.7 26.7% | 793.8 29.3% | 1,039.9 32.3% | 1,014.5 30.1% | 1,217.7 33.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is IDEXX Laboratories, Inc.'s EBIT to Interest coverage?
As of today, Microsoft Corp's last 12-month EBIT to Interest coverage is 61.4x, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual EBIT to Interest coverage for IDEXX Laboratories, Inc. have been 30.2x over the past three years, and 28.6x over the past five years.
2) Is IDEXX Laboratories, Inc.'s EBIT to Interest coverage Good?
As of today, IDEXX Laboratories, Inc.'s EBIT to Interest coverage is 61.4x, which is higher than industry median of (14.3x). It indicates that IDEXX Laboratories, Inc.'s EBIT to Interest coverage is Good.